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Abstract
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting 23
approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal 24 uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the 25 fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase 26 fetal growth in the uterus. 27
Maternal uterine artery gene therapy presents a promising treatment strategy for IUGR, with 28 the use of adenoviral vectors encoding for proteins such as Vascular Endothelial Growth 29
Factor (VEGF) demonstrating improvements in fetal growth and neonatal outcome in 30 preclinical studies. Mechanistically, maternal VEGF gene therapy delivered to the uterine 31 arteries increases uterine blood flow and enhances vascular relaxation short term, while 32 reducing vascular contractility long term. It also leads to vascular remodeling with increased 33 endothelial cell proliferation in the perivascular adventitia of uterine arteries. Safety 34 assessments suggest no vector spread to the fetus and no adverse risk to the mother or fetus; a 35 clinical trial is in development. This article assesses research into VEGF maternal uterine 36 artery directed gene therapy for IUGR, investigating the use of transgenes and vectors, their 37 route of administration in obstetrics, and the steps that will be needed to take this treatment 38 modality into the clinic. 39 M A N U S C R I P T
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Intrauterine growth restriction 45
Optimal fetal growth depends on normal functioning maternal, placental and fetal factors and 46 the external environmental, on the background of a genetically pre-determined growth 47 M A N U S C R I P T
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brain. However, delivering the fetus in severe early onset IUGR adds additional risks to the 70 baby from extreme prematurity (9). In this situation the question of viability also arises, and 71 decision making with parents is challenging (10). Substantial improvements in morbidity and 72 mortality can be seen if delivery of such pregnancies occurs even one week later (e.g. from 73
26 to 27 weeks) and if there are modest increases in birth weight (eg 100g). In an EU and US 74 multi-centre observational study of babies born after severe early onset FGR, median survival 75 gained per day in utero between 24 and 27 weeks of gestation was 2% (range 1.1 -2.6) (11). 76
It is in these severe early-onset cases of IUGR that novel therapeutics are initially being 77 considered, where the benefit of gaining in gestation length or improved fetal weight might 78 outweigh the potential risks of a novel therapy. If it is found to be safe and efficacious there 79 is potential to use new therapies in more moderate FGR, which affects a larger number of 80 pregnancies. 81
82
Gene therapy
83
Gene therapy allows for the transfer of genetic material into a target cell with the aim of 84 achieving therapeutic benefit. Since the first gene therapy trials in the 1990s, the hope has 85 been that gene therapy could improve the management and outcomes of genetic diseases, 86 particularly single-gene disorders. There are currently over 1800 completed or on-going gene 87 therapy clinical trials, of which over two-thirds are for cancer. In 2012 GlyberaTM, a 88 treatment for familial lipoprotein lipase deficiency became the first gene therapy product to 89 be approved for licensing in Europe (12). Gene therapies are increasingly reaching clinical 90 use for treatment of a wide range of inherited single gene disorders such as haemophilia, 91 thalassaemia, immunodeficiencies and metabolic storage disorders. Concerns about germline 92 gene transfer and off-target effects in the fetus however, are holding back translation into the 93 clinic of fetal-directed gene therapy (13) and currently, it is not considered ethical. SeriousM A N U S C R I P T
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maternal obstetric diseases such as pre-eclampsia and IUGR also affect the fetus and neonate 95 long term. Targeting gene therapy to the mother and not the fetus, with a view to improve 96 fetal outcome is considered acceptable from an ethical, legal and regulatory perspective (14) . 97
Appreciating the molecular basis of untreatable obstetric diseases has lead to an 98 understanding of the potential role that gene therapy could play (8) be preferable to target increased VEGF availability to the maternal uteroplacental circulation 146 using locally delivered gene therapy, rather than increase systemic maternal VEGF levels. 147
Therapeutic angiogenesis is the term given to the induction of new blood vessel formation by 148 delivering angiogenic genes to ischemic tissues (30). Ad.VEGF gene therapy is being 149 translated into the clinic for ischemic cardiovascular disorders, including acute myocardial 150 infarction, chronic cardiac ischemia, peripheral artery disease and stroke. Therapeutic 151 angiogenesis can also be applied in the maternal uteroplacental circulation as a way to 152 improve fetal growth in utero, as described below. Equally it is now known that the type of VEGF isoform can critically regulate VEGF 165 function. This can be through the endothelial response, for example, the 165 and 121 166 isoforms of VEGF-A can elicit differential signal transduction and endothelial responses 167 through programming VEGFR2 endocytosis, ubiquitylation and proteolysis (31).
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neuropilin-1 differentiates the effects of VEGF-A 165 that binds both and mediates angiogenic 170 sprouting and endothelial cell organization, from VEGF-A 121 that binds neither and therefore 171 lacks these functions (32). 172
The impact of Ad.VEGF on uterine blood flow (UBF) was first examined at mid-gestation in 173 uncompromised normal sheep pregnancies using the VEGF-A 165 isoform. Results are 174 summarised in Table 1 guinea pig is associated with considerable morbidity and mortality, a less invasive technique 231 of administration has been developed using a thermosensitive Pluronic gel, which is applied 232 externally to the uterine and radial arteries at laparotomy to achieve transduction with 233
Ad.VEGF-A 165 or Ad.LacZ at 30-34 days gestation (term = 65) (37). Using this technique, 234
Ad.VEGF-A 165 treatment improved fetal growth at term and a lower brain: liver weight ratio, 235 implying that brain sparing had been mitigated (Table 2) (38). More recently in a second 236 delivered cohort, there are no adverse effects on perinatal morbidity or mortality, improved 237 postnatal growth and amelioration of the increase in adult blood pressure associated with 238 IUGR in this animal model (submitted, Table 2 ). 239
The improvements in fetal birth weight and uterine artery blood flow in IUGR-animal models 240 treated with Ad.VEGF establish VEGF as a transgenic factor with therapeutic benefit in 241 IUGR-affected pregnancies, making it a strong candidate for translation into human clinical 242 trials. Extrapolating from animal studies to humans is challenging particularly for pregnancyM A N U S C R I P T
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and where they may be fundamental differences in VEGF biology and VEGF measurement 245
techniques (39). 246 247 248
Risks of maternal uterine artery VEGF gene therapy 249 An important consideration for any prenatal therapy is safety, some data of which is 250 presented in Table 1 and 2. This therapy aims to reduce or eliminate the adverse effects of 251 poor growth in the fetus without exposing the fetus to significant amounts of the vector. 252
Transfer of a gene therapy across the placenta to the fetus in significant quantities would be 253 undesirable, as it would risk germline transmission and may have adverse effects on fetal 254 development. Current evidence suggests that the extent of placental transfer depends on the 255 vector, the animal, the route of administration, and the gestation age at which it is 256 administered. In the pre-clinical studies of maternal Ad.VEGF gene transfer, local delivery to 257 the uterine arteries has been achieved either by direct injection combined with proximal 258 occlusion of the vessel or by external application of a thermolabile Pluronic gel to the vessel 259 wall (37). These delivery methods do not lead to evidence of detectable vector in the sheep or 260 guinea pig fetus. Exposure of human placental villous explants to high dose Ad. vector 261
showed that, where the syncytiotrophoblast was deficient there was occasional transduction 262 of the underlying cytotrophoblast, but no evidence of the vector crossing the basement 263 membrane (40). In translation to clinical practice this could be replicated using a balloon 264 catheter, introduced into each uterine artery in turn using x-ray guided interventional 265 radiology. This technique has been used for over 30 years to treat fibroids and manage 266 postpartum haemorrhage, and is now being used increasingly during pregnancy, with 267 catheters and deflated balloons placed into the uterine arteries before Caesarean section whenM A N U S C R I P T
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Vector modification of the fetal germ line could theoretically occur following maternal gene 270 therapy. This would be dependent first on whether the vector reached the fetus, and then was 271 able to access the germline. The gestational age of the fetus and route of injection are 272 probably the determining factors for germline gene transfer risk. Early gestation direct fetal 273 gene therapy leads to germline transmission when retroviral vectors are injected into the 274 peritoneal cavity of first trimester fetal sheep (60), and after first trimester but not second 275
trimester intraperitoneal injection of lentiviral vectors into fetal macaque monkeys (61). 276
Compared with direct fetal gene therapy therefore, maternal uterine artery gene therapy for 277
IUGR that is will be conducted after mid gestation should carry a very low risk of fetal 278 germline transduction. This is an important safety consideration in any clinical trial protocol. conducted by the EVERREST consortium, maternal gene therapy was for the majority of 292 stakeholders considered to be acceptable if there was clear fetal benefit (44). Most women 293 felt they would be able to make informed decisions about taking part in such a trial whilstM A N U S C R I P T
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pregnant, so long as they were provided with the information required to make an 295 autonomous decision. The primary aim of the the phase I clinical trial is to determine safety. 296
The planned route of administration is via interventional radiology guided uterine artery 297 injection, with a temporary cessation of blood flow during vector injection of up to 5 minutes. 298
There are concerns that systemic gene transfer with generalised transgenic VEGF expression 299 would detrimentally lower maternal blood pressure and reduce uteroplacental perfusion, such 300 as was seen after systemic administration of sildenafil citrate in FGR sheep pregnancy (45). 301
Temporary cessation of uterine artery blood flow could potentially worsen fetal hypoxia. It is 302 now appreciated from radiological studies however, that the the uterus is provided by a rich 303 blood supply from the ovarian, cervical and vaginal arteries including a system of utero-304 ovarian communicating arteries (46)(47)(48). Careful monitoring of fetal wellbeing and 305 prompt release of uterine artery occlusion will be needed in any clinical trial protocol. 306
Other potential risks include vascular leak, which is less likely when using VEGF-D rather 307 than VEGF-A isoforms, and the pro-inflammatory state from VEGF-induced macrophage 308 activation. Reassuringly long term studies on adenovirus gene therapy show an excellent 309 safety profile up to 10 years after clinical trials of local intracoronary and lower limb 310 administration (49)(50), and Ad.VEGF-D ∆N∆C is being tested in a phase III clinical trial for 311 refractory angina pectoris "ReGenHeart" ClinicalTrials.gov Identifier:NCT03039751. 312
The consortium has developed a prospective "natural history" cohort, to carefully define the 313 characteristics and outcomes of pregnancies affected by severe early onset IUGR (51) which 314 is also refining the inclusion criteria for a clinical trial. During this study the consortium has 315 also studied which angiogenic markers may be most useful for defining the inclusion criteria 316 in the trial. Monitoring the change in concentration of sFlt1 and its ratio with PlGF may be 317 useful to predict the onset of pre-eclampsia and IUGR (52), and a similar approach is beingM A N U S C R I P T
pregnancies take part, while achieving sufficient numbers of babies to allow long term to 320 evaluate safety and efficacy. 321
322
Conclusion
323
Local expression of VEGF in the uterine arteries increases uterine blood flow, alters uterine 324 artery vascular reactivity, increases angiogenesis and improves fetal growth in IUGR 325 pregnancies without apparent maternal or fetal harm. Translation to the clinic will be 326 complex as getting informed patient consent and demonstrating safety will be key. Findings 327 from preclinical studies however suggest that maternal VEGF gene therapy is promising as a 328 therapy for severe early onset IUGR. 
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